The Benefits of Early Engagement with Patient-Reported Outcomes Strategies in Clinical Product Development

Abstract

In this article, Jenny Retzler explains how consideration of PRO strategies from the very beginning of clinical product development can not only ensure optimal collection of PRO data for the demonstration of treatment benefits, but also generate evidence to inform trial design, product development, and marketing decisions.

Authors

Jenny Retzler Matthew Taylor

Full Text
Back to January/February 2017
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×